Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023 PR Newswire - Mon Oct 16, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023 PR Newswire - Sun Oct 15, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting PR Newswire - Wed Oct 11, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Wall Street - shutterstock_1321462394
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap Barchart - Tue Oct 10, 2023

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
ZS : 176.89 (-0.70%)
NOC : 473.75 (+1.04%)
LMT : 466.68 (+0.84%)
DAL : 52.20 (-1.38%)
AAL : 14.25 (-2.73%)
DDOG : 112.40 (-11.48%)
PEP : 178.02 (+1.25%)
ELIS.FP : 22.500 (+3.78%)
IMUX : 1.3800 (+2.99%)
AKRO : 22.02 (-0.41%)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire - Mon Oct 9, 2023

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as...

IMUX : 1.3800 (+2.99%)
Immunic to Participate in Scientific Conferences in October PR Newswire - Wed Oct 4, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Immunic to Participate in Industry and Investor Conferences in September PR Newswire - Wed Sep 6, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis PR Newswire - Thu Aug 17, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire - Thu Aug 3, 2023

– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective...

IMUX : 1.3800 (+2.99%)
Immunic to Participate in Investor and Scientific Conferences in August PR Newswire - Tue Aug 1, 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.3800 (+2.99%)

Barchart Exclusives

Should Amazon Stock Follow The ‘Magnificent 7’ Trend and Start Paying a Dividend? Barchart - Tue May 7, 6:30PM CDT
While fellow 'Magnificent 7' peers like Alphabet and Meta Platforms have recently initiated dividends, Amazon might not do so for at least the next couple of years. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot